Big Pharma: Dealing With Fewer Biotech Targets


There have been 2,000-plus deals over the past two years in pharma and biotech, but the pace isn't likely sustainable The torrid pace of consolidation among drugmakers is bound to slow at some point. But that doesn't mean deal bankers and lawyers will be idle in 2016.



from Biotech News